Report Library

Thelansis’s “Erosive Esophagitis (EE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erosive Esophagitis (EE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Congenital Diarrheal Disorder (CDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Diarrheal Disorder (CDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “IDH1-Mutated Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IDH1-Mutated Acute Myeloid Leukemia (AML) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Necrotizing Enterocolitis (NEC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Necrotizing Enterocolitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Recurrent C. Difficile Infections (rCDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent C. Difficile Infections (rCDI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Avascular Necrosis (Osteonecrosis) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Avascular Necrosis (Osteonecrosis) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Advanced Metastatic Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced Metastatic Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Extensive-Stage Small-Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced and Metastatic Esophageal Squamous Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Thelansis’s “Barrett's Esophagus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Barrett's Esophagus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).